Valneva SE (NASDAQ:VALN) Short Interest Down 56.3% in May

Valneva SE (NASDAQ:VALN - Get Free Report) saw a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 2,100 shares, a drop of 56.3% from the May 15th total of 4,800 shares. Currently, 0.0% of the company's shares are short sold. Based on an average daily trading volume, of 74,200 shares, the days-to-cover ratio is currently 0.0 days.

Hedge Funds Weigh In On Valneva

A number of institutional investors have recently modified their holdings of the company. GAMMA Investing LLC acquired a new position in Valneva in the 1st quarter valued at $94,000. ABC Arbitrage SA bought a new position in shares of Valneva in the fourth quarter worth about $84,000. Finally, Wells Fargo & Company MN lifted its position in shares of Valneva by 14.3% during the 4th quarter. Wells Fargo & Company MN now owns 246,766 shares of the company's stock worth $1,079,000 after purchasing an additional 30,859 shares during the last quarter. Institutional investors own 11.39% of the company's stock.

Valneva Stock Down 3.1%

VALN traded down $0.19 on Tuesday, reaching $5.88. 23,279 shares of the company traded hands, compared to its average volume of 42,514. The company has a market cap of $500.35 million, a price-to-earnings ratio of -45.23 and a beta of 1.81. The company has a debt-to-equity ratio of 0.70, a current ratio of 2.78 and a quick ratio of 2.25. The stock's 50 day moving average price is $6.46 and its 200-day moving average price is $5.97. Valneva has a 52-week low of $3.62 and a 52-week high of $8.66.

Valneva (NASDAQ:VALN - Get Free Report) last posted its quarterly earnings results on Wednesday, May 7th. The company reported ($0.13) earnings per share for the quarter, topping analysts' consensus estimates of ($0.40) by $0.27. The company had revenue of $51.79 million during the quarter, compared to the consensus estimate of $41.80 million. Valneva had a negative return on equity of 3.93% and a negative net margin of 4.35%. On average, sell-side analysts expect that Valneva will post 0.13 EPS for the current fiscal year.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on VALN shares. Guggenheim cut their price target on shares of Valneva from $15.00 to $14.00 and set a "buy" rating on the stock in a report on Thursday, May 8th. HC Wainwright restated a "buy" rating and issued a $17.00 target price on shares of Valneva in a report on Tuesday, April 15th.

About Valneva

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; IXCHIQ, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus; and VLA2001, an inactivated whole-virus COVID-19 vaccine.